The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

NCT07052877 · tracked via the Priya Life Science Australia tracker

Sponsor

Royal North Shore Hospital

Phase

Observational

Started

2025-12-11

Last updated

2026-08-13

Condition(s) studied

GlioblastomaGlioblastoma Multiforme (GBM)

Investigational drug(s) / intervention(s)

PSMA PET/CT scan

PSMA PET/CT scan: PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.

Study summary

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour * Confirmed glioblastoma IDH1/2 wildtype (WHO2021) * For bevacizumab treatment as per treating physician * Able to comply with trial requirements Exclusion Criteria: * No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment) * Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope * Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging * Does not fulfill PBS requirements for bevacizumab * Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Primary outcome measure(s)

Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration. — Prior to first administration of bevacizumab to 6 weeks after.

Trial sites (1)

Facility	City	Region	Status
Royal North Shore Hospital	Saint Leonards	New South Wales	Recruiting

More Royal North Shore Hospital trials in Australia

De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE) Recruiting

Advanced Techniques for Single-fraction Palliative Radiotherapy Versus ASPIRE-single Active, not recruiting

Pelvis Adaptive Radiotherapy (ART) Recruiting

Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking Active, not recruiting

Markerless Image Guidance Using Intrafraction Kolovoltage X-ray Imaging for Lung Cancer Radiotherapy Active, not recruiting

Other trials for the same condition

Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma Recruiting

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma Recruiting

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations Active, not recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Recruiting

Targeted Pediatric High-Grade Glioma Therapy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07052877 on ClinicalTrials.gov ↗ ← All trials in Australia